WallStSmart
XERS

Xeris Pharmaceuticals Inc

NASDAQ: XERS · HEALTHCARE · BIOTECHNOLOGY

$6.02
-1.15% today

Updated 2026-04-29

Market cap
$1.04B
P/E ratio
0.00
P/S ratio
3.56x
EPS (TTM)
$0.00
Dividend yield
52W range
$4 – $10
Volume
1.9M

Xeris Pharmaceuticals Inc (XERS) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2016201720182019202020212022202320242025
Revenue$1.07M$1.56M$2.46M$2.72M$2.72M$49.59M$110.25M$163.91M$203.07M$291.85M
Revenue growth (YoY)+44.7%+58.4%+10.4%+0.0%+1721.8%+122.3%+48.7%+23.9%+43.7%
Cost of revenue$8000.00$4000.00$42000.00$1.60M$1.60M$13.32M$22.63M$28.64M$36.83M$53.41M
Gross profit$1.07M$1.55M$2.42M$1.12M$1.12M$36.27M$87.61M$135.27M$166.24M$238.43M
Gross margin99.3%99.7%98.3%41.1%41.1%73.1%79.5%82.5%81.9%81.7%
R&D$10.24M$20.17M$40.65M$60.44M$60.44M$25.16M$20.97M$22.34M$25.56M$31.16M
SG&A$4.06M$8.02M$21.11M$63.06M$73.73M$125.72M$137.75M$146.09M$163.48M$182.37M
Operating income$-13.23M$-26.63M$-59.34M$-122.38M$-122.38M$-115.16M$-81.94M$-44.01M$-33.65M$24.90M
Operating margin-1230.8%-1711.4%-2407.5%-4496.0%-4496.0%-232.2%-74.3%-26.8%-16.6%8.5%
EBITDA$-13.09M$-26.38M$-57.22M$-119.57M$-117.80M$-113.67M$-69.31M$-23.73M$-13.99M$12.71M
EBITDA margin-1217.8%-1695.2%-2321.1%-4392.6%-4327.6%-229.2%-62.9%-14.5%-6.9%4.4%
EBIT$-13.21M$-26.55M$-57.53M$-122.38M$-118.88M$-115.55M$-81.98M$-36.90M$-26.62M$554000.00
Interest expense$2000.00$2000.00$2.54M$7.16M$7.16M$7.18M$14.10M$26.61M$33.17M$29.08M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-13.21M$-26.55M$-60.08M$-125.58M$-125.58M$-122.72M$-94.66M$-62.26M$-54.84M$554000.00
Net income growth (YoY)-101.0%-126.3%-109.0%+0.0%+2.3%+22.9%+34.2%+11.9%+101.0%
Profit margin-1228.7%-1706.6%-2437.3%-4613.5%-4613.5%-247.5%-85.9%-38.0%-27.0%0.2%